(secondQuint)TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin.

 The drug being tested in this study is called TAK-438.

 TAK 438 is being tested to assess the effect of multiple oral doses of clarithromycin on the pharmacokinetics of TAK-438.

 The study will enroll approximately 16 healthy adult male participants of non-Japanese origin.

 Participants will be assigned: - TAK-438 40 mg - Clarithromycin 500 mg All participants will be asked to take 2 tablet of TAK-438 20 mg orally, once on Days 1 and 8 along with Clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.

 This single center trial will be conducted in Europe.

 The overall time to participate in this study is maximum of 44 days.

 Participants will be confined to site for 10 days, and a final visit after 4 days after discharge from the unit for a follow-up assessment.

.

 TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin@highlight

The purpose of this study is to evaluate the effect of multiple oral doses of clarithromycin on the pharmacokinetics of TAK-438 and its metabolites in healthy male adult participants following a single oral dose of TAK-438.

